Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment

T cell lymphoma (TCL) is a highly heterogeneous group of diseases with a poor prognosis and low 5-year overall survival rate. The current therapeutic regimens have relatively low efficacy rates. Clinical studies of single-target chimeric antigen receptor T cell (CAR-T cell) therapy in T lymphocytes...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Baijin Xia, Keming Lin, Xuemei Wang, FeiLi Chen, Mo Zhou, Yuzhuang Li, Yingtong Lin, Yidan Qiao, Rong Li, Wanying Zhang, Xin He, Fan Zou, Linghua Li, Lijuan Lu, Cancan Chen, WenYu Li, Hui Zhang, Bingfeng Liu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2023-09-01
Schriftenreihe:	Molecular Therapy: Oncolytics
Schlagworte:	bispecific CAR-T cells CD30 CD5 nanobodies T cell lymphoma
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2372770523000542
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!